Corbus Pharmaceuticals Holdings, Inc. (CRBP): Sean F. Moran , CFO of Corbus Pharmaceuticals Holdings, Inc. purchased 30,000 shares on May 18, 2016. The Insider buying transaction was reported by the company on May 18, 2016 to the Securities and Exchange Commission. The shares were purchased at $2.39 per share for a total value of $71,700.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Dec 11, 2015, Sean F. Moran (CFO) purchased 1,000 shares at $1.56 per share price.On Nov 24, 2015, Yuval Cohen (CEO) purchased 535 shares at $1.76 per share price.Also, On Nov 23, 2015, Barbara White (Chief Medical Officer) purchased 4,000 shares at $1.67 per share price.On Aug 21, 2015, Sumner Burstein (10% owner) sold 200,000 shares at $3.04 per share price.
Corbus Pharmaceuticals Holdings Inc: On Thursday, May 19, 2016 heightened volatility was witnessed in Corbus Pharmaceuticals Holdings Inc which led to swings in the share price. The shares opened for trading at $2.4 and hit $2.6 on the upside , eventually ending the session at $2.55, with a gain of 6.25% or 0.15 points. The heightened volatility saw the trading volume jump to 6,21,733 shares. The 52-week high of the share price is $4.22 and the company has a market cap of $96 M . The 52-week low of the share price is at $1.01.
Corbus Pharmaceuticals Holdings Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare life-threating inflammatory-fibrotic diseases. The Company’s lead product candidate Resunab is an oral anti-inflammatory drug that is being developed for the treatment of inflammatory disorders such as cystic fibrosis (CF) and scleroderma. The Company has completed the Phase I safety studies for the treatment of scleroderma and cystic fibrosis. The Company has submitted an Investigational New Drug Application (INDA) to the United States Food and Drug Administration (FDA) for a Phase IIa double-blind placebo controlled clinical study evaluating Resunab in patients with diffuse scleroderma. Pre-clinical and Phase I clinical studies (123 subjects) have shown Resunab to have a favorable safety profile coupled with suitable potency in pre-clinical models of inflammation and fibrosis.